Cargando…

Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial

IMPORTANCE: Mavacamten has shown clinical benefits in global studies for patients with obstructive hypertrophic cardiomyopathy (oHCM), but evidence in the Asian population is lacking. OBJECTIVE: To evaluate the safety and efficacy of mavacamten compared with placebo for Chinese patients with symptom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Zhuang, Li, Liwen, Li, Xiaoyan, Wang, Jian’an, Zhang, Qing, Li, Zhanquan, Peng, Daoquan, Yang, Ping, Ma, Wei, Wang, Fang, Jin, Wei, Cheng, Xiang, Sun, Jing, Fu, Yiqun, Lyu, Cheng, Zhang, Shuyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463173/ https://www.ncbi.nlm.nih.gov/pubmed/37639259 http://dx.doi.org/10.1001/jamacardio.2023.3030

Ejemplares similares

Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy
por: Tian, Zhuang, et al.
Publicado: (2023)

Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions
por: Dong, Tiffany, et al.
Publicado: (2023)

Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy
por: Scholtz, Smita, et al.
Publicado: (2023)

The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients
por: DeVries, J Hans, et al.
Publicado: (2023)

Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten
por: Mathai, Susan, et al.
Publicado: (2022)

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
por: Braunwald, Eugene, et al.
Publicado: (2023)

The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review
por: Edelberg, Jay M., et al.
Publicado: (2022)

Concerns with Patient Reported Outcome Measurement and Value Claims for Therapy Response: The Case of Mavacamten and Symptomatic Hypertrophic Cardiomyopathy (SHCM)
por: Langley, Paul C
Publicado: (2022)

Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy
por: Taddei-Allen, Patty
Publicado: (2022)

Efficacy and safety of mavacamten in treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis
por: Memon, Areeba, et al.
Publicado: (2023)

Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials
por: Rabiee Rad, Mehrdad, et al.
Publicado: (2023)

Analyzing safety and effectiveness of Mavacamten in comparison with placebo for managing hypertrophic cardiomyopathy: a systemic review and meta-analysis
por: Rangwala, Hussain Sohail, et al.
Publicado: (2023)

Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment
por: Wang, Kai, et al.
Publicado: (2023)

Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca(2+) flux caused by thin filament hypertrophic cardiomyopathy mutations
por: Sparrow, Alexander J., et al.
Publicado: (2020)

Mavacamten for hypertrophic cardiomyopathy: effectiveness and value: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Beinfeld, Molly, et al.
Publicado: (2022)

Mavacamten: First Approval
por: Keam, Susan J.
Publicado: (2022)

Correction to: Mavacamten: First Approval
por: Keam, Susan J.
Publicado: (2022)

Identifying Obstructive Hypertrophic Cardiomyopathy from Nonobstructive Hypertrophic Cardiomyopathy: Development and Validation of a Model Based on Electrocardiogram Features
por: Guo, Lanyan, et al.
Publicado: (2023)

Hypertrophic Obstructive Cardiomyopathy
por: Cohen, Lawrence S.
Publicado: (1972)

A case report and analysis of hypertrophic obstructive cardiomyopathy causing an illusion of aortic stenosis
por: Wang, Ying, et al.
Publicado: (2018)

Effects of omecamtiv mecarbil and mavacamten in isolated human atrium
por: Abella, Lina Maria Rayo, et al.
Publicado: (2022)

Outcome of alcohol septal ablation in mildly symptomatic patients with hypertrophic obstructive cardiomyopathy: A comparison with medical therapy
por: Li, Peijin, et al.
Publicado: (2021)

Midterm Outcome After Septal Myectomy and Medical Therapy in Mildly Symptomatic Patients With Hypertrophic Obstructive Cardiomyopathy
por: Sun, Jiejun, et al.
Publicado: (2022)

How Symptomatic Should a Hypertrophic Obstructive Cardiomyopathy Patient Be to Consider Alcohol Septal Ablation?
por: Jones, Brandon M., et al.
Publicado: (2017)

Risk of glomerular filtration rate decline in patients with hypertrophic cardiomyopathy and obstructive sleep apnoea
por: Wang, Shao-Yun, et al.
Publicado: (2017)

ECHOCARDIOGRAPHY FOR HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY
por: Irpachi, Kalpna, et al.
Publicado: (2017)

Temporal and spatial variations of soil C, N contents and C:N stoichiometry in the major grain-producing region of the North China Plain
por: Yang, Huan, et al.
Publicado: (2021)

Thoracoscopic Trans-mitral Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy in the Elderly
por: Wei, Peijian, et al.
Publicado: (2022)

Retrospective Analysis of Risk Factors for Related Complications of Chemical Ablation on Hypertrophic Obstructive Cardiomyopathy
por: Li, Cheng-Yang, et al.
Publicado: (2019)

Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database Study
por: Owens, Anjali T., et al.
Publicado: (2022)

Uric acid is associated with cardiac death in patients with hypertrophic obstructive cardiomyopathy
por: GAO, Jun, et al.
Publicado: (2021)

Indications for Surgery in Obstructive Hypertrophic Cardiomyopathy
por: Sherrid, Mark V.
Publicado: (2020)

Hemorrhagic stroke caused by moyamoya disease in a patient with obstructive hypertrophic cardiomyopathy
por: Liu, Sheng, et al.
Publicado: (2021)

Atypical Infantile-onset Pompe Disease with Hypertrophic Cardiomyopathy
por: Quan, Jun-Jun, et al.
Publicado: (2017)

Haploinsufficiency of syncoilin leads to hypertrophic cardiomyopathy
por: Fan, Liang-Liang, et al.
Publicado: (2022)

Future Role of New Negative Inotropic Agents in the Era of Established Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy
por: Maron, Barry J., et al.
Publicado: (2022)

Hypertrophic cardiomyopathy
por: Antunes, Murillo de Oliveira, et al.
Publicado: (2020)

Hypertrophic Cardiomyopathy
por: Butt, Asra K., et al.
Publicado: (2023)

First-in-man application of Liwen RF™ ablation system in the treatment of drug-resistant hypertrophic obstructive cardiomyopathy
por: Wang, Zihao, et al.
Publicado: (2022)

Lipid overload - a culprit for hypertrophic cardiomyopathy?
por: Zhang, Lilei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gv1bp6sue91fnai57ma62mrnqt